The company reported a net loss attributable to American Shared Hospital Services of $(1,553,000) in 2025, a significant decline from net income of $2,186,000 in 2024. Total revenue in 2025 was $28,082,000, a 0.9% decrease from $28,340,000 in 2024. Revenue from the leasing segment decreased by $3,076,000 in 2025, primarily due to lower Proton Beam Radiation Therapy (PBRT) volumes and the expiration of three Gamma Knife contracts. Direct patient service segment revenue increased by $2,973,000 in 2025, driven by the Puebla, Mexico facility and the three Rhode Island facilities acquired in May 2024. Gamma Knife procedures decreased by 13.6% to 937 in 2025 from 1,084 in 2024, mainly due to contract expirations and downtime for equipment upgrades in Peru. PBRT procedures decreased by 21.1% to 4,056 in 2025 from 5,139 in 2024, attributed to normal cyclical fluctuations. LINAC procedures increased by 92.0% to 28,147 in 2025 from 14,662 in 2024, largely due to the Rhode Island Acquisition and the Puebla facility. Costs of revenue increased by $3,863,000 (20.2%) to $23,018,000 in 2025, primarily due to higher operating costs from direct patient service facilities. Cash and cash equivalents, including restricted cash, decreased by $7,563,000 to $3,712,000 at December 31, 2025, from $11,275,000 at December 31, 2024. The company had a working capital deficit of $5,724,000 at December 31, 2025, compared to a working capital surplus of $15,853,000 at December 31, 2024. The company is not in compliance with multiple financial covenants (minimum fixed-charge coverage ratio, maximum funded debt-to-EBITDA ratio, and Minimum Cash Covenant of $5,000,000) under its Credit Agreement with Fifth Third Bank as of September 30, 2025, and December 31, 2025. Fifth Third Bank has suspended the Revolving Loan Commitment and has the right to accelerate payment obligations under the Credit Agreement, which matures on April 9, 2026. The company's non-compliance with the Credit Agreement could be deemed a cross-default under the DFC Loan, raising substantial doubt about its ability to continue as a going concern. A material weakness in internal control over financial reporting was identified as of December 31, 2025, due to insufficient personnel and resources in accounting and finance.